AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23595134 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating albumin increases
Number of subjects: 14
Study 23595134 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐γ increases
Number of subjects: 14
Study 21788756 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 167
Study 21788756 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 167
Study 21788756 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 167
Study 19489933 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdenture supported by two IMZ implants (group A)
Number of subjects: 60
Study 19489933 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdenture supported by four IMZ implants (group B)
Number of subjects: 60
Study 16824986 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management interventions
Number of subjects: 102
Study 12624284 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) apolipoprotein E (apoE) concentration in patients with SAH
Number of subjects: 0
Study 12624284 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) S100B concentration in patients with SAH
Number of subjects: 0
Study 12624284 — intervention group
Group type: COMPARATOR
Intervention: Cerebrospinal fluid (CSF) apolipoprotein E (apoE) concentration in control group
Number of subjects: 0
Study 10841968 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (8 mg slow-release, twice daily for 3 weeks)
Number of subjects: 12
Study 10841968 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 3 weeks)
Number of subjects: 12
Study 9285607 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen
Number of subjects: 19
Study 9285607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 8396841 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estriol (3 mg/day for 4 weeks followed by 2 mg/day for a further 6 weeks)
Number of subjects: 0
Study 8396841 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care programme based on an algorithm model
Number of subjects: 0
Study 8396841 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 2943594 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg)
Number of subjects: 8
Study 2943594 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (10 mg)
Number of subjects: 8
Study 2943594 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg)
Number of subjects: 8
Study 2943594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31631992 — intervention group
Group type: EXPERIMENTAL
Intervention: CSE+MRT (Core Stabilization Exercise + Myofascial Release Technique)
Number of subjects: 45
Study 31631992 — intervention group
Group type: COMPARATOR
Intervention: CSE (Core Stabilization Exercise)
Number of subjects: 45
Study 25939582 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (Cool Kids CBT program)
Number of subjects: 12
Study 25939582 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical care
Number of subjects: 12
Study 26335910 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered CBT
Number of subjects: 273
Study 26335910 — intervention group
Group type: COMPARATOR
Intervention: Internet-delivered Education
Number of subjects: 273
Study 25366952 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pump (IABP)
Number of subjects: 17
Study 25366952 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 17
Study 22533710 — intervention group
Group type: EXPERIMENTAL
Intervention: U‐PRIM (screening and monitoring intervention using routine healthcare data)
Number of subjects: 5000
Study 22533710 — intervention group
Group type: EXPERIMENTAL
Intervention: U‐CARE (nurse‐led multidisciplinary intervention program)
Number of subjects: 5000
Study 22533710 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 5000
Study 19930246 — intervention group
Group type: EXPERIMENTAL
Intervention: ETT size 6.0
Number of subjects: 100
Study 19930246 — intervention group
Group type: COMPARATOR
Intervention: ETT size 7.0
Number of subjects: 100
Study 19930246 — intervention group
Group type: EXPERIMENTAL
Intervention: ETT size 6.0 and 7.0
Number of subjects: 100
Study 17641591 — intervention group
Group type: EXPERIMENTAL
Intervention: Active heating strategies (steady-state non-specific active heating - NSAH)
Number of subjects: 7
Study 17641591 — intervention group
Group type: EXPERIMENTAL
Intervention: Active heating strategies (intermittent soccer-specific active heating - SSAH)
Number of subjects: 7
Study 17641591 — intervention group
Group type: COMPARATOR
Intervention: Passive heating (hot bath - PH)
Number of subjects: 7
Study 17641591 — intervention group
Group type: COMPARATOR
Intervention: Rest control trial (CON)
Number of subjects: 7
Study 14503056 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy plus Tongxinluo (TXL) Capsule
Number of subjects: 46
Study 14503056 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 46
Study 11018096 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy regimens from phase II studies with expected power of 0.62 and 0.58
Number of subjects: 21
Study 11018096 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy regimens from six other phase II studies
Number of subjects: 21
Study 9346990 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) therapy
Number of subjects: 5
Study 9346990 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 5
Study 8358664 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosol (0.12% chlorhexidine)
Number of subjects: 0
Study 8358664 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 0
Study 3003020 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol, 50 mg once/day
Number of subjects: 17
Study 3003020 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 118551, 20 mg 3 times/day
Number of subjects: 17
Study 3003020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 30208956 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaping the Social intervention
Number of subjects: 10190
Study 30208956 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 10190
Study 26059831 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice Training Program
Number of subjects: 204
Study 26059831 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 204
Study 26059831 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Groups
Number of subjects: 204
Study 23803593 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-to-visit blood pressure variability (VTV-BPV) measured by the coefficient of variation (CV) and average real variability in systolic blood pressure (SBP).
Number of subjects: 1844
Study 22463944 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal treatment
Number of subjects: 80
Study 22463944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 20144188 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-guided focussed medium-energy density ESWT treatments (3 sessions at weekly intervals)
Number of subjects: 0
Study 20144188 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 18953177 — intervention group
Group type: EXPERIMENTAL
Intervention: P-APC-PCI complex level in patients with frequent AVFG failures (n = 8)
Number of subjects: 35
Study 18953177 — intervention group
Group type: COMPARATOR
Intervention: P-APC-PCI complex level in patients with less frequent AVFG failures (n = 27)
Number of subjects: 35
Study 16167962 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 hours administration of misoprostol
Number of subjects: 450
Study 16167962 — intervention group
Group type: COMPARATOR
Intervention: 36-48 hours administration of misoprostol
Number of subjects: 450
Study 12870373 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium flush infusion into the aortic root before cross-clamp removal
Number of subjects: 0
Study 12870373 — intervention group
Group type: COMPARATOR
Intervention: Placebo flush infusion into the aortic root before cross-clamp removal
Number of subjects: 0
Study 10385632 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA therapy (600 mg/d)
Number of subjects: 527
Study 8874423 — intervention group
Group type: EXPERIMENTAL
Intervention: One-ring treatment group (17 eyes)
Number of subjects: 28
Study 8874423 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-ring treatment group (8 eyes)
Number of subjects: 28
Study 8874423 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 28
Study 1997518 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide (50 micrograms/day in trial I; 75-100 micrograms/day in trial II)
Number of subjects: 157
Study 1997518 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine (5 mg/day in trial I; 7.5-10 mg/day in trial II)
Number of subjects: 157
Study 1997518 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 157
Study 1997518 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 157
Study 6662933 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed male case history
Number of subjects: 90
Study 6662933 — intervention group
Group type: COMPARATOR
Intervention: Depressed female case history
Number of subjects: 90
Study 31446992 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib starting dose of 20 mg/day, with potential increase in 10 mg increments up to 50 mg/day
Number of subjects: 46
Study 30559773 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic stapedotomy
Number of subjects: 42
Study 30559773 — intervention group
Group type: COMPARATOR
Intervention: Microscopic stapedotomy
Number of subjects: 42
Study 26844688 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin-D and calcium replacement (800 IU Vitamin-D and 500 mg Calcium once daily)
Number of subjects: 87
Study 26844688 — intervention group
Group type: COMPARATOR
Intervention: No vitamin-D and calcium replacement
Number of subjects: 87
Study 24418213 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 80
Study 24418213 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 80
Study 22008377 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 5 or 10 mg
Number of subjects: 16
Study 22008377 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 50 g
Number of subjects: 16
Study 22008377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 19887218 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface electrical stimulation program (frequency 45 Hz, impulse 200 micros, 10s on/10s off) for 8 weeks on the biceps brachii of both arms.
Number of subjects: 30
Study 19887218 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group).
Number of subjects: 30
Study 17258104 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured nursing intervention program including music therapy, drama, and group therapy
Number of subjects: 0
Study 17258104 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what intervention was used)
Number of subjects: 0
Study 12825865 — intervention group
Group type: COMPARATOR
Intervention: Regular dose of omeprazole (20 mg/day for 3 days)
Number of subjects: 101
Study 12825865 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of omeprazole (80 mg bolus + 8 mg/h infusion/day for 3 days)
Number of subjects: 101
Study 10806604 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase (30, 40, or 50 mg intravenous bolus)
Number of subjects: 159
Study 10806604 — intervention group
Group type: COMPARATOR
Intervention: Alteplase (100 mg intravenous as accelerated 90-minute infusion)
Number of subjects: 159
Study 10806604 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase (approximately 0.5 mg/kg)
Number of subjects: 159
Study 8932540 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg verapamil
Number of subjects: 48
Study 8932540 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 mg verapamil
Number of subjects: 48
Study 8932540 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 mg verapamil
Number of subjects: 48
Study 8932540 — intervention group
Group type: EXPERIMENTAL
Intervention: 540 mg verapamil
Number of subjects: 48
Study 1641292 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon gamma (1 million units/m2, three times a week for 24 weeks)
Number of subjects: 35
Study 1641292 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferons alfa and gamma (5 MU/m2 for 12 weeks followed by 1 MU/m2 of interferon gamma, three times a week)
Number of subjects: 35
Study 1641292 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 35
Study 6679514 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisuride (0.0250 mg single oral dose)
Number of subjects: 45
Study 6679514 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisuride
Number of subjects: 45
Study 6679514 — intervention group
Group type: COMPARATOR
Intervention: Pizotiphene
Number of subjects: 45
Study 30839426 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive verbal suggestions regarding the benefits of acupuncture needling
Number of subjects: 96
Study 30839426 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive treatment-related suggestions
Number of subjects: 96
Study 30839426 — intervention group
Group type: COMPARATOR
Intervention: Neutral verbal suggestions regarding the benefits of acupuncture needling
Number of subjects: 96
Study 28552083 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist Supportive Clinical Management
Number of subjects: 120
Study 28552083 — intervention group
Group type: EXPERIMENTAL
Intervention: Maudsley Model Anorexia Nervosa Treatment for Adults
Number of subjects: 120
Study 28552083 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Cognitive Behavioural Therapy
Number of subjects: 120
Study 28552083 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study 26316741 — intervention group
Group type: EXPERIMENTAL
Intervention: Olodaterol 2 µg
Number of subjects: 328
Study 26316741 — intervention group
Group type: EXPERIMENTAL
Intervention: Olodaterol 5 µg
Number of subjects: 328
Study 26316741 — intervention group
Group type: EXPERIMENTAL
Intervention: Olodaterol 10 µg
Number of subjects: 328
Study 26316741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study 23159168 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic treatment in conjunction with orthognathic surgery
Number of subjects: 121
Study 23159168 — intervention group
Group type: COMPARATOR
Intervention: Control group (age and gender matched subjects)
Number of subjects: 121
Study 21529928 — intervention group
Group type: EXPERIMENTAL
Intervention: 380 mg XR‐NTX
Number of subjects: 250
Study 21529928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 19624833 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based programme
Number of subjects: 0
Study 19624833 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face group treatment programme
Number of subjects: 0
Study 19624833 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study 16449111 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% intrauterine lidocaine infusion
Number of subjects: 80
Study 16449111 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 80
Study 16121931 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitherapist (15 mg/dl Lentinan, particulate size of 0.2 microm)
Number of subjects: 0
Study 10224992 — intervention group
Group type: EXPERIMENTAL
Intervention: Resource mothers program
Number of subjects: 83
Study 10224992 — intervention group
Group type: COMPARATOR
Intervention: Control group (phenylketonuric women without resource mothers)
Number of subjects: 83
Study 9138755 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-transplant patients
Number of subjects: 690
Study 9138755 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin tumors
Number of subjects: 690
Study 9138755 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoproliferative disorders
Number of subjects: 690
Study 9138755 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Hodgkin's lymphoma
Number of subjects: 690
Study 9138755 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynecological tumors
Number of subjects: 690
Study 9138755 — intervention group
Group type: EXPERIMENTAL
Intervention: Miscellaneous tumors
Number of subjects: 690
Study 9138755 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 690
Study 1941003 — intervention group
Group type: EXPERIMENTAL
Intervention: General practice recruitment strategy
Number of subjects: 400
Study 1941003 — intervention group
Group type: COMPARATOR
Intervention: Local community approach
Number of subjects: 400
Study 1941003 — intervention group
Group type: COMPARATOR
Intervention: Electoral roll recruitment strategy
Number of subjects: 400
Study 6310996 — intervention group
Group type: EXPERIMENTAL
Intervention: Amdinocillin plus cefoxitin
Number of subjects: 45
Study 6310996 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin alone
Number of subjects: 45
Study 31953790 — intervention group
Group type: EXPERIMENTAL
Intervention: Diroximel fumarate (DRF) 462 mg
Number of subjects: 0
Study 31953790 — intervention group
Group type: COMPARATOR
Intervention: Dimethyl fumarate (DMF) 240 mg
Number of subjects: 0
Study 30565327 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 10
Study 30565327 — intervention group
Group type: COMPARATOR
Intervention: Sham patch
Number of subjects: 10
Study 29800295 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-pulsed fidaxomicin
Number of subjects: 0
Study 29800295 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 0
Study 26738971 — intervention group
Group type: EXPERIMENTAL
Intervention: Pen included with questionnaire
Number of subjects: 7625
Study 26738971 — intervention group
Group type: COMPARATOR
Intervention: Control group (questionnaire alone)
Number of subjects: 7625
Study 24888488 — intervention group
Group type: EXPERIMENTAL
Intervention: Siltuximab 15 mg/kg every 4 weeks + best supportive care (BSC)
Number of subjects: 76
Study 24888488 — intervention group
Group type: COMPARATOR
Intervention: Placebo + best supportive care (BSC)
Number of subjects: 76
Study 22356258 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 766
Study 22356258 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 766
Study 22356258 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg (partial responders adjusted to dosing every 8 weeks)
Number of subjects: 766
Study 22356258 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg (partial responders adjusted to dosing every 8 weeks)
Number of subjects: 766
Study 22356258 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 766
Study 20530973 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil (E-CMF: Epirubicin 100 mg/m² on day 1, CMF: 600 mg/m² cyclophosphamide, 40 mg/m² methotrexate, 600 mg/m² 5-fluorouracil on days 1 and 8)
Number of subjects: 244
Study 20530973 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel followed by epirubicin and vinorelbine (T-EV: Paclitaxel 175 mg/m² on day 1, Epirubicin 75 mg/m² on day 1, Vinorelbine 25 mg/m² on days 1 and 8)
Number of subjects: 244
Study 18613793 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbapenems combined with thymosin alpha(1) and ulinastatin (CTU group)
Number of subjects: 120
Study 18613793 — intervention group
Group type: COMPARATOR
Intervention: Carbapenems and placebo (CP group)
Number of subjects: 120
Study 16485513 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg/day for the first month and 8 mg/day for the remaining 11 months)
Number of subjects: 1252
Study 16485513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1252
Study 11920300 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination B vaccine (recombinant Plasmodium falciparum ring‐infected erythrocyte surface antigen and 2 merozoite surface proteins (MSP1 and MSP2) formulated in oil‐based adjuvant)
Number of subjects: 120
Study 11920300 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination B vaccine
Number of subjects: 120
Study 10325814 — intervention group
Group type: EXPERIMENTAL
Intervention: Trophic feeding (0.5 ml/h if birthweight < 1 kg, 1 ml/h if ≥ 1 kg) in addition to parenteral nutrition
Number of subjects: 70
Study 10325814 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition alone
Number of subjects: 70
Study 8949568 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human GH (rhGH) 0.5 U/kg/week
Number of subjects: 28
Study 2021299 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Number of subjects: 75
Study 2021299 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal psychotherapy
Number of subjects: 75
Study 2021299 — intervention group
Group type: COMPARATOR
Intervention: Behavior therapy
Number of subjects: 75
Study 31072023 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BRJ)
Number of subjects: 29
Study 31072023 — intervention group
Group type: COMPARATOR
Intervention: Beetroot juice (BRJ) with Vitamin C
Number of subjects: 29
Study 28094031 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent in-center hemodialysis (six times per week)
Number of subjects: 332
Study 28094031 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent nocturnal home hemodialysis (six times per week)
Number of subjects: 332
Study 28094031 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemodialysis (three times per week)
Number of subjects: 332
Study 25710276 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical BAK-preserved tafluprost
Number of subjects: 195
Study 25710276 — intervention group
Group type: COMPARATOR
Intervention: SofZia-preserved travoprost
Number of subjects: 195